The Objective Response Tate (ORR) of Patients Who Received a PD-L1 Inhibitor Plus Chemotherapy Was 63%, And The ORR Was 50% in Those Who Received Chemotherapy Alone .
The Median Progression-Free Survival (PFS) Was 7.53 Months (95% CI, 4.40-9.14) in Patients Receiving a PD-L1 Inhibitor Plus Chemotherapy, Compared With a Median PFS of 5.43 Months (95% CI, 4.20-6.73; P=.080) in Those Receiving Chemotherapy Alone .
The Median OVERALL SURVIVAL (OS) Was 17.50 Months in Patients Receiving a PD-L1 Inhibitor Plus Chemotherapy (95% CI, 13.30 To Not Reached), Compared With 9.87 Months (95% CI, 5.70-17.70; P=.055) in Those Receiving Chemotherapy Alone . ...